Action Regencell Bioscience - RGC

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Dernier

3,70

Prix Achat

3,70

Prix Vente

4,00

Volume échangé

0,00 Fourchette du Jour 0,00

3,00 Plage de 52 semaines 32,44

Cap du marché

48,148M

Clôture Veille

3,70

Ouverture

Dernière Transaction

3.98

Dernière heure de transaction

10:03:07

Volume financier

VWAP

Volume moyen (3 m)

25 498

Actions en circulation

13 012 866

Rendement du Dividende

Ratio Cours sur Bénéfices

-11,19

Bénéfice par action (BPA)

-0,33

Chiffre d'affairess

Bénéfice net

-4,3M

Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration. Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.

Secteur

Medicinal Chems,botanicl Pds

Industrie

Medicinal Chems,botanicl Pds

Site Web

www.regencellbioscience.com

Siège social

Hong Kong, Hkg

Fondé

Regencell Bioscience Holdings Ltd est coté dans le secteur Medicinal Chems,botanicl Pds de la NASDAQ avec le ticker RGC. Le dernier cours de clôture d'Regencell Bioscience était de US$3,70. Au cours de la dernière année, les actions de Regencell Bioscience ont été négociées dans une fourchette de prix de US$ 3,00 à US$ 32,44.

Regencell Bioscience compte actuellement 13 012 866 actions en circulation. La capitalisation boursière d'Regencell Bioscience est de US$48,15 million. Regencell Bioscience a un ratio cours/bénéfice (ratio PE) de -11.19.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial

- The Sik-Kee Au TCM Brain Theory® Assessment for ADHD and ASD (“SKATBT-A3”), which measures the effectiveness of the treatment on the patient’s...

Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period

Regencell Bioscience Holdings Limited (NASDAQ: RGC): Results of EARTH efficacy trial EARTH Efficacy Trials Period of trial 30 January 2022...

Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focusing on the research...

Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focusing on the research...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.06	1.64835164835	3.64	3.864	3.41	6120	3.66242147	CS
4	-1	-21.2765957447	4.7	7.3125	3.41	34421	4.07134133	CS
12	-2.42	-39.5424836601	6.12	7.3125	3.41	25498	4.87728825	CS
26	-5.05	-57.7142857143	8.75	12.5	3.41	68601	6.20040752	CS
52	-4.09	-52.5032092426	7.79	32.44	3	82032	9.43338868	CS
156	-33.3	-90	37	48.29	3	30267	11.34103621	CS
260	-8.3	-69.1666666667	12	59	3	85642	25.88061887	CS

RGC - Frequently Asked Questions (FAQ)

What is the current Regencell Bioscience share price?

The current share price of Regencell Bioscience is US$ 3,70

How many Regencell Bioscience shares are in issue?

Regencell Bioscience has 13 012 866 shares in issue

What is the market cap of Regencell Bioscience?

The market capitalisation of Regencell Bioscience is USD 48,15M

What is the 1 year trading range for Regencell Bioscience share price?

Regencell Bioscience has traded in the range of US$ 3,00 to US$ 32,44 during the past year

What is the PE ratio of Regencell Bioscience?

The price to earnings ratio of Regencell Bioscience is -11,19

What is the reporting currency for Regencell Bioscience?

Regencell Bioscience reports financial results in USD

What is the latest annual profit for Regencell Bioscience?

The latest annual profit of Regencell Bioscience is USD -4,3M

What is the registered address of Regencell Bioscience?

The registered address for Regencell Bioscience is 11/F FIRST COMMERCIAL BUILDING, 33-35 LEIGHTON ROAD, HONG KONG, 999077

What is the Regencell Bioscience website address?

The website address for Regencell Bioscience is www.regencellbioscience.com

Which industry sector does Regencell Bioscience operate in?

Regencell Bioscience operates in the MEDICINAL CHEMS,BOTANICL PDS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
MDBHMDB Capital Holdings LLC	US$ 11,14 (61,33%)	8
BSBKBogota Financial Corporation	US$ 12,41 (59,92%)	8
TCBSTexas Community Bancshares Inc	US$ 25,44 (57,52%)	6
INTGIntergroup Corporation	US$ 21,94 (53,64%)	7
LYTLytus Technologies Holdings PTV Ltd	US$ 0,3403 (52,88%)	30,15M
TLFTandy Leather Factory Inc	US$ 2,20 (-59,41%)	7
NSINational Security Emerging Markets Index ETF	US$ 11,01 (-59,03%)	8
MTVAMetaVia Inc	US$ 0,6765 (-59,00%)	302
NVDWTradr 1.75X Long NVDW Weekly ETF	US$ 13,01 (-55,14%)	6
TACTTransAct Technologies Inc	US$ 2,01 (-54,42%)	1
ADTXAditxt Inc	US$ 0,1343 (22,09%)	58,27M
LYTLytus Technologies Holdings PTV Ltd	US$ 0,3386 (52,11%)	30,16M
TRUGTruGolf Holdings Inc	US$ 0,5368 (31,25%)	9,57M
DGLYDigital Ally Inc	US$ 0,1139 (8,68%)	7,15M
RSLSReShape Lifesciences Inc	US$ 1,56 (44,44%)	6,73M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Regencell Bioscience Holdings Ltd (RGC)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Regencell Bioscience Holdings Ltd

RGC Dernières nouvelles

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial

Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period

Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RGC - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Regencell Bioscience Holdings Ltd (RGC) Cours

Regencell Bioscience Holdings Ltd (RGC)

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Statistiques et détails clés

À propos de Regencell Bioscience Holdings Ltd

RGC Dernières nouvelles

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial

Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period

Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

RGC - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités